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In the transition to multicellularity during evolution indi-
vidual cells gave up autonomous control over whether to
grow and divide, live or die. These processes are regulated
instead by a variety of intercellular signals and the network
of signal-transduction pathways they activate. Thus, prolif-
eration of a population of cells can be regulated in concert
in response to triggers that reflect the needs of the whole
organism, such as patterning cues, developmental stage, and
environmental conditions. Over the past several years,
studies in mammalian cell culture and model organisms
such as Drosophila have identified as a dedicated regulator of
cell growth and proliferation in response to nutrition the
signaling pathway from insulin at the cell surface to phos-
phatidylinositol (PI) 3-kinase and the protein kinase Akt
(also called protein kinase B, PKB) inside the cell [1]. Muta-
tions in this pathway result in profound changes in cell,
organ and organism size, and its activation is a critical step
in a number of types of cancer. Intensive efforts have there-
fore been directed towards gaining a molecular understand-
ing of the mechanisms by which insulin signaling promotes
growth. Three recent studies [2-4], including a paper by
Jünger et al. in this issue of Journal of Biology [2], have now
addressed the role played by gene expression in mediating
insulin-controlled growth in Drosophila.
Signaling responses to insulin
The proximal steps downstream of insulin binding are well
understood [5] (Figure 1). In response to ligand binding, the
insulin receptor phosphorylates insulin receptor substrate
(IRS) proteins (encoded by the chico gene in Drosophila),
which act as docking sites for the class I PI 3-kinase. Acti-
vated PI 3-kinase increases the levels of the second messen-
ger phosphatidylinositol 3,4,5-triphosphate (PIP3) at the cell
membrane; the accumulation of PIP3 is opposed by the
phosphatase activity of a negative regulator of insulin sig-
naling, the tumor suppressor PTEN. An important down-
stream effector of PIP3 is the serine threonine protein kinase
Akt/PKB. In response to PI 3-kinase activation, interaction
between PIP3 and the pleckstrin homology domain of Akt
causes recruitment of Akt to the cell membrane, where it is
further activated by one or more additional kinases. Akt
appears to be the major critical target of PIP3 signaling in
Drosophila, as mutations in Akt that block its ability to bind
PIP3 can restore viability to animals with high levels of PIP3
caused by mutations in PTEN [6]. 
Two signaling branches downstream of Akt have been iden-
tified (Figure 1). One branch of this pathway leads to activa-
tion of the target of rapamycin (TOR) and p70 S6 kinases,
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© 2003 BioMed Central Ltd which promote cell growth through a number of effects
including stimulation of ribosome biogenesis [7]. The direct
target of Akt in this case appears to be the product of the
tuberous sclerosis complex 2 gene [8], TSC2, which was
recently found to function as a negative regulator of the
small GTPase Rheb, an upstream activator of TOR [9]. Akt
phosphorylates and inactivates TSC2, thereby allowing
increased activity of Rheb, TOR, and S6 kinase.
A second pathway downstream of Akt was initially identi-
fied through genetic studies in Caenorhabditis elegans.
Insulin signaling mediates responses to nutrient levels in
C. elegans by regulating the formation of a developmentally
arrested juvenile form known as the dauer, which can
survive starvation conditions for an extended period [10].
Loss-of-function mutations in insulin signaling components
mimic starvation, leading to inappropriate dauer formation.
A number of years ago, Daf16 was identified as a negative
regulator of this insulin-dependent response in worms [11].
Mutations in daf16 can completely suppress the dauer
induction caused by reduced insulin signaling. Daf16 was
found to encode a transcriptional regulator of the Forkhead-
box type O (FOXO) class of Forkhead-related factors, thus
indicating that control of gene expression is a major output
of insulin signaling in worms. Subsequent studies in cul-
tured mammalian cells extended these results, showing that
FOXO factors are negatively regulated by the insulin/PI 3-
kinase/Akt pathway. In response to increased insulin levels,
activated Akt phosphorylates FOXO on multiple sites,
resulting in its nuclear exclusion [12]. Upon reduced insulin
signaling, FOXO becomes dephosphorylated and accumu-
lates in the nucleus, where it acts to regulate the transcrip-
tion of a number of target genes.
Growth control by FOXO factors
Could FOXO-regulated transcription play a role in growth
regulation by the insulin/PI 3-kinase pathway? Several lines
of evidence point to such a role. First, overexpression of any
of the three mammalian FOXO homologs, FOXO1,
FOXO3a or FOXO4, leads to growth arrest in a variety of
cell types [12]. Increased levels of insulin can suppress the
growth arrest caused by overexpression of wild-type FOXO,
but not of FOXO mutants lacking Akt phosphorylation
sites. Second, FOXO factors regulate expression of a number
of regulators of cell proliferation including p27kip1, cyclin D,
and the Retinoblastoma-related protein p107. Induction of
p27kip1, an inhibitor of cyclin-dependent kinases, appears to
be a critical step in cell-cycle arrest by FOXO. The transcrip-
tion of p27kip1 is directly induced by FOXO factors in
response to low insulin levels, and cells lacking the kip1
gene are highly resistant to growth inhibition by expression
of FOXO or inactivation of PI 3-kinase [13]. In addition,
transcription of cyclin D is negatively regulated by FOXO,
and forced expression of cyclin D can partially bypass
FOXO-induced arrest [14]. Finally, a number of chromoso-
mal translocations involving FOXO members are associated
with neoplasias. For example, a t(1;13)(p36q14) transloca-
tion found in rhabdomyosarcomas results in fusion of a
portion of FOXO1 with the PAX7 gene [15].
A potential limitation to the conclusions from these studies
is that most were performed in cultured, transformed cells
using non-physiological levels of transgene expression.
Thus, the relevance of FOXO factors and their potential
targets in growth mediated by insulin and PI 3-kinase in vivo
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Figure 1
The dFOXO protein mediates a transcriptional response to insulin
signaling. Under conditions of abundant nutrients, dFOXO is retained in
an inactive state in the cytoplasm due to phosphorylation by Akt. When
insulin levels fall, dFOXO is dephosphorylated and translocated into the
nucleus, where it stimulates transcription of 4E-BP and presumably
other negative regulators of growth. In addition, active dFOXO
increases expression of the insulin receptor gene [4], which may result


















3-kinaseremains unclear. Indeed, genetic studies have suggested that
downregulation of TSC2 and subsequent activation of the
TOR/S6 kinase pathway may be the central function of
insulin signaling in regulating cell growth [16].
As now described by Puig et al. [4], Jünger et al. [2] and
Kramer  et al. [3], addressing this question in Drosophila
allows analysis of both overexpressed and endogenous
FOXO  in a variety of in vivo conditions. The fly genome
encodes a single FOXO ortholog, dFOXO, whose sequence
includes three Akt phosphorylation consensus sites similar
to those found in mammalian FOXOs and nematode
Daf16. As in these proteins, phosphorylation of dFOXO is
stimulated by Akt activation in response to insulin, and this
results in turn in its cytoplasmic localization and transcrip-
tional inactivation [4]. Each of the three studies [2-4]
demonstrates that overexpression of dFOXO or mammalian
FOXO proteins in developing Drosophila tissues results in a
significant reduction in growth. Importantly, more severe
phenotypes are obtained by expression of FOXO proteins
lacking their Akt phosphorylation sites, or by coexpression
of wild type dFOXO with an inhibitory version of PI 3-
kinase. The degree of growth suppression by dFOXO also
increases in response to nutrient deprivation [2], which has
been shown to reduce the levels of insulin-like protein
expression. Together these results provide in vivo support for
the idea that FOXO proteins are negative regulators of
growth in response to conditions of low insulin signaling.
Although these experiments were conducted in vivo, the
results suffer the usual caveats of studies based on over-
expression. Indeed, it was found that the growth inhibition
caused by dFOXO expression is due in part to induction of
necrotic cell death [2], a phenotype not observed upon com-
plete loss of insulin/PI 3-kinase signaling. This suggests that
the overexpression phenotypes may not reflect normal
FOXO function. To directly test the physiological require-
ment for dFOXO in regulating growth, Jünger et al. [2] gener-
ated loss-of-function mutations in the dFOXO gene. The
predicted phenotype of disrupting a negative growth regula-
tor is unrestrained growth, as observed in PTEN  and TSC
mutants. Surprisingly, this was not the case in the dFOXO
mutants: flies lacking dFOXO were found to grow to a
normal size [2]. Thus, despite its ability to potently inhibit
growth when overexpressed, dFOXO is apparently not
required for growth suppression under normal developmen-
tal conditions. In contrast, a genetic requirement for dFOXO
was observed when insulin-signaling levels were experimen-
tally lowered. Loss of FOXO significantly suppressed the
reduced growth phenotype of mutations in the insulin
receptor, chico, PI 3-kinase and Akt genes [2]. Thus, under
normal conditions, insulin/PI 3-kinase signaling appears to
be sufficient to maintain dFOXO in a phosphorylated state,
rendering it inactive, cytoplasmic, and therefore largely irrel-
evant. When insulin signaling is reduced, however, dFOXO
is required to provide full growth inhibition. 
Like most models however, the current one has difficulty
incorporating a few experimental observations. Although
most parts of the fly grew normally in the dFOXO mutant,
the wings were found to be reduced in size, an unexpected
result for a growth-suppressor mutation. In addition, dFOXO
mutants suppressed the overgrowth phenotype caused by
mutations in PTEN, a negative regulator of insulin signaling.
These results suggest that in some situations dFOXO may
play a positive role in regulating growth. Recent studies have
found that transient downregulation of Akt signaling and
activation of FOXO3a is required for mitotic progression in
NIH 3T3 cells [17]. This finding may partly explain why
dFOXO mutants do not have an overgrowth phenotype -
they fail to go through sufficient mitoses - and may also
account for previous observations that constitutive expres-
sion of PI 3-kinase in the Drosophila wing can increase the
rate of cell growth but not cell division [18].
Insulin signaling regulates growth by controlling both cell
size and cell number, and mutations in different compo-
nents of this pathway in Drosophila  have been shown to
cause distinct effects on these parameters. For example, the
small flies resulting from mutations in the chico/IRS1 gene
are comprised of both smaller and fewer cells [19], whereas
loss of dS6K function causes a reduction in cell size without
affecting cell number [20]. Where does dFOXO fit into this
scheme? In general, most of the results in the recent studies
[2-4] suggest that dFOXO exerts its effects largely through
changes in cell number: dFOXO mutants were found to sup-
press the reduction in cell number but not cell size caused
by chico mutations [2]. Furthermore, Puig et al. [4] found
that the small eyes and wings resulting from dFOXO over-
expression were comprised of fewer cells of normal size [4].
Thus, changes in cell size and cell number are genetically
separable outcomes of insulin signaling, and dFOXO repre-
sents the first identified insulin signaling component that
regulates primarily cell number.
These distinctions become somewhat blurred, however,
when one considers the actual cellular processes that
control the final number and size of cells in an organism,
namely cell growth, cell division, and cell death. In the case
of dFOXO overexpression, for example, the reduction in cell
number but not cell size implies that rates of cell growth
and division are decreased in a balanced fashion, thus
maintaining normal cell size (Figure 2). In chico mutants,
on the other hand, this balance must be slightly disrupted,
with the rate of cell growth being reduced to a greater extent
than that of cell division, resulting in both fewer and
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amongst insulin-signaling components in their effects on
final cell size and number may reflect rather modest or even
trivial differences during development, such as the develop-
mental stage at which a gene product becomes limiting.
Indeed, in contrast to the conclusions of Puig et al. [4],
Kramer  et al. [3] found that overexpression of dFOXO
caused reductions in both cell size and number; this dis-
crepancy is likely to be due in part to differences in timing
of overexpression, with Kramer et al. expressing dFOXO later
in development, in primarily post-mitotic cells, thereby pre-
venting a balanced reduction of growth and division. Thus,
classifications of insulin signaling components on the basis
of their effect on cell number and cell size probably repre-
sent somewhat artificial distinctions that do not reflect criti-
cal differences in their cellular functions.
What are the transcriptional targets that contribute to
growth regulation by insulin signaling? The results of
genome-wide expression analyses suggest that the number
of FOXO-regulated genes is likely to be rather large. Puig et
al. [4] identified 277 genes that were upregulated in cul-
tured  Drosophila  cells expressing constitutively active
dFOXO. Jünger et al. [2] took a complementary approach,
identifying genes whose expression decreased in response to
insulin. In addition, the expression profiles of Drosophila
larvae subjected to nutrient deprivation in vivo have been
assayed [21]. One target gene identified in each of these
studies is d4E-BP, a negative regulator of translation that
acts by binding and inhibiting the translation-initiation
factor eIF4E. The 4E-BPs are well-established targets of
phosphorylation by the TOR-dependent pathway, which
disrupts the association between 4E-BP and eIF4E; the
current results therefore indicate that both the expression
and activity of d4E-BP are negatively regulated by insulin
signaling (Figure 1). Interestingly, loss-of-function muta-
tions in d4E-BP appear to have no effect on growth in an
otherwise wild-type background, but they were found to
suppress the reduction in growth caused by reduced insulin
signaling, in a manner remarkably similar to that of dFOXO
mutants [2]. In addition, Puig et al. [4] also identified the
insulin receptor gene as being transcriptionally activated by
dFOXO, suggesting a negative feedback loop that may serve
to buffer the effects of alterations in insulin levels. 
Together, these new studies in Drosophila significantly
broaden our understanding of the multiple layers of
insulin-mediated growth regulation. Control of gene
expression by FOXO factors in response to insulin allows
integration of transcriptional activities with other growth-
related processes regulated by insulin, such as protein syn-
thesis, carbohydrate metabolism and survival. A challenge
for the future is to explore how these processes interact,
and to determine what role transcription plays in their reg-
ulation. For example, by coordinating the expression of
genes that induce growth arrest with genes required to
survive quiescence, FOXO factors may provide a compre-
hensive response to conditions of low insulin or nutrient
levels [22]. In addition, it will be important to understand
how differences in cell type and developmental context can
influence the transcriptional and physiological response to
FOXO activity, regulating cell growth and proliferation in
some cases and differentiation in others. Identification of
the physiologically relevant target genes in these processes
should provide further insights into the important process
of insulin signaling.
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